Shire sells eight 'non-core' products for $213 million

Share this article:

Shire said today that it is selling eight “non-core” products to Spanish company Almirall for $213 million.

“The divested products are no longer core to Shire's strategy of building market leading positions in specialty markets,” the company said in a statement.

Shire said its focus is moving forward will be on building its attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases businesses and, with its recent in-licensing of Juvista (human recombinant), to build a new specialty area of regenerative medicine.

There are eight products being sold in the transaction. They include:

* Lodine (etodolac) for treatment of rheumatoid arthritis.

* Colazide (balsalazide) for treatment of mild to active ulcerative colitis.

* Meptid (meptazinol hydrochloride) for treatment of pain.

*Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

*Robaxin (methocarbamol) for relief of pain from muscle injuries, spasms, sprains and strains.

*Mintec (peppermint oil) for the relief of discomfort associated with irritable bowel syndrome.

*Solaraze (diclofenac sodium) is a topical preparation for the treatment of actinic keratoses.

*Vaniqa (eflornithine) is a topical prescription medicine for treating unwanted facial hair in women.
 
Almirall chairman and CEO Jorge Gallardo said in a statement the acquisition would expand his company's international presence and “reinforces our position as one of the key European specialty pharmaceutical companies.”

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.